| __timestamp | Ionis Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 241751000 | 46425000 |
| Thursday, January 1, 2015 | 322292000 | 81491000 |
| Friday, January 1, 2016 | 344320000 | 94291000 |
| Sunday, January 1, 2017 | 374644000 | 121827000 |
| Monday, January 1, 2018 | 414604000 | 160524000 |
| Tuesday, January 1, 2019 | 466000000 | 200000000 |
| Wednesday, January 1, 2020 | 535000000 | 275000000 |
| Friday, January 1, 2021 | 643000000 | 328100000 |
| Saturday, January 1, 2022 | 833000000 | 463800000 |
| Sunday, January 1, 2023 | 899625000 | 565000000 |
| Monday, January 1, 2024 | 901530000 | 731100000 |
In pursuit of knowledge
In the competitive world of biotechnology, innovation is the lifeblood of progress. Over the past decade, Ionis Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc. have been at the forefront of this innovation race, significantly increasing their research and development (R&D) investments.
From 2014 to 2023, Ionis Pharmaceuticals has consistently led the charge, with its R&D expenses growing by approximately 272%, peaking in 2023. This commitment underscores Ionis's dedication to pioneering new treatments and therapies. Meanwhile, Neurocrine Biosciences has also shown a remarkable upward trend, with its R&D spending increasing by over 1,100% during the same period. This surge highlights Neurocrine's strategic focus on expanding its research capabilities.
These investments reflect the companies' unwavering commitment to innovation, promising a future rich with groundbreaking advancements in biotechnology.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Research and Development Investment: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Neurocrine Biosciences, Inc. or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Ionis Pharmaceuticals, Inc. vs Viking Therapeutics, Inc.: Strategic Focus on R&D Spending
Ionis Pharmaceuticals, Inc. vs Evotec SE: Strategic Focus on R&D Spending